Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Lee's Pharm Accelerates Eye Drop Development as Part of New Ophthalmic Division

publication date: Mar 26, 2019

Lee's Pharm of Hong Kong announced it will accelerate its development of a eye drop treatment for ophthalmic indications. In 2012, Lee's in-licensed greater China rights to RGN-259 from RegeneRx Bio as part of a three-drug deal. Lee's recently completed a new ophthalmic drug manufacturing and warehousing facility in Guangzhou. RGN-259 is a candidate for dry eye syndrome, neurotrophic keratitis (NK), and other persistent corneal disorders. More details....

Stock Symbols: (HK: 950) (OTCQB: RGNX)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.